Results 41 to 50 of about 8,510 (199)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK‐rearranged lung cancer [PDF]

, 2022
Lorlatinib, a third‐generation anaplastic lymphoma kinase (ALK)‐tyrosine kinase inhibitor (TKI) with a broad coverage against ALK mutations, has demonstrated dramatic effects in patients with ALK‐rearranged lung cancer.
Akagi, Kazumasa, Dotsu, Yosuke, Gyotoku, Hiroshi, Imamura, Erika, Mukae, Hiroshi, Ono, Sawana, Sen, Triparna, Takemoto, Shinnosuke, Taniguchi, Hirokazu, Yamada, Tadaaki, Yamaguchi, Hiroyuki, Yano, Seiji   +11 more
core   +1 more source

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj, Bergsland, Emily K, Bivona, Trever G, Damato, Bertil, Fogh, Shannon, Miller, Vincent A, Urisman, Anatoly, Wang, Victoria E, Wolfe, John, Young, Lauren   +9 more
core   +1 more source

Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC

Cell Death Discovery, 2022
Lorlatinib is a promising third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been approved for treating ALK-positive non-small-cell lung cancer (NSCLC) patients with previous ALK-TKI treatment failures.
Conghua Lu, Rui Yu, Chong Zhang, Caiyu Lin, Yuanyao Dou, Di Wu, Yonghong Pan, Tao Peng, Huan Tang, Rui Han, Yong He   +10 more
doaj   +1 more source

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC [PDF]

, 2023
Introduction: Circulating tumor DNA (ctDNA) has been used as a biomarker for prognostication and response to treatment. Here, we evaluate ctDNA as a potential biomarker for response to lorlatinib, a third-generation ALK tyrosine kinase inhibitor in ...
Calella, Anna Maria, Chiu, Chao Hua, Ferrara, Roberto, Kim, Hye Ryun, Kowalski, Dariusz M., Martini, Jean François, Polli, Anna, Shaw, Alice T., Shepard, Deborah, Solomon, Benjamin J., Soo, Ross A., Teraoka, Shunsuke, Toffalorio, Francesca, Tomasini, Pascale, van der Wekken, Anthonie J.   +14 more
core   +3 more sources

Targeting anaplastic lymphoma kinase (ALK) alleviates synaptic dysfunction associated with C9orf72 haploinsufficiency [PDF]

Alzheimers Dement
Abstract Background Hexanucleotide repeat expansions in C9orf72 are the most common genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The repeat expansions cause C9orf72 haploinsufficiency and reduced C9orf72 protein expression.
Kartono B, Attisano L, Robertson J.
europepmc   +2 more sources

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Respirology Case Reports, 2021
Alectinib treatment is effective in patients with anaplastic lymphoma kinase (ALK) gene rearrangement‐positive non‐small cell lung cancer (NSCLC; hereafter ALK‐positive NSCLC) who exhibit central nervous system (CNS) relapse and poor performance status ...
Kota Sasaki, Yusuke Yokota, Toshihito Isojima, Mayumi Fujii, Kengo Hasui, Yu Chen, Kensuke Saito, Takenori Takahata, Seiko Kindaichi, Atsushi Sato   +9 more
doaj   +1 more source

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

Pharmaceuticals, 2020
In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors.
Maximilian J. Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll, Romana Wass, Elmar Brehm, Gudrun Absenger, Tatjana Bundalo, Peter Errhalt, Matthias Urban, Arschang Valipour   +16 more
doaj   +1 more source

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Frontiers in Oncology, 2021
IntroductionRecently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC ...
SiNi Li, SiNi Li, JianHe Li, LiuBao Peng, YaMin Li, YaMin Li, XiaoMin Wan   +6 more
doaj   +1 more source